Immunovant (NasdaqGS:IMVT) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Company ParticipantsAlex Thompson - Managing DirectorBen Zimmer - CEOCorinne Jenkins - Managing DirectorDavid Risinger - Senior Managing DirectorDerek Archila - Managing DirectorDouglas Tsao - Managing DirectorMatt Gline - CEOPrakhar Agrawal - Managing DirectorStephanie Lee - Head of Investor RelationsYatin Suneja - Senior Managing DirectorConference Call ParticipantsAshwani Verma - Research AnalystBrian Cheng - Executive Directo ...

Immunovant (NasdaqGS:IMVT) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Company ParticipantsAlex Thompson - Managing DirectorBen Zimmer - CEOCorinne Jenkins - Managing DirectorDavid Risinger - Senior Managing DirectorDerek Archila - Managing DirectorDouglas Tsao - Managing DirectorMatt Gline - CEOPrakhar Agrawal - Managing DirectorStephanie Lee - Head of Investor RelationsYatin Suneja - Senior Managing DirectorConference Call ParticipantsAshwani Verma - Research AnalystBrian Cheng - Executive Directo ...

Immunovant (NasdaqGS:IMVT) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Speaker1Good day, and thank you for standing by. Welcome to the Roivant third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your ques ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State or other jurisdiction of incorporati ...

Immunovant anticipates sharing topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate to severe thyroid eye disease (TED) in the first half of calendar year 2026. In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in each of GD and MG. Financial Highlights for Fiscal Third Quarter Ended December 31, 2025: Cash Position: As of December 31, 2025, Immunovant's cash and cash equivalents totaled $994.5 million, provi ...

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s di ...

Core Viewpoint - Immunovant, Inc. (IMVT) shares have shown a modest gain of 0.4% over the past four weeks, closing at $26, with analysts suggesting a potential upside of 55% based on a mean price target of $40.31 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $13.5, indicating variability among analysts; the lowest estimate is $16.00 (38.5% decline), while the highest is $57.00 (119.2% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism regarding IMVT's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.9%, with one estimate moving higher and no negative revisions [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Company Overview - Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, utilizing anti-FcRn technology to create targeted treatments [3]. Financial Results Announcement - Immunovant will report its financial results for the third quarter ending December 31, 2025, and provide a business update on February 6, 2026, at 8:00 a.m. ET [1]. Conference Call Access - Investors can access the conference call by registering online, with details available on Immunovant's website under the "News & Events" section [2].

Core Viewpoint - Immunovant, Inc. (IMVT) shows potential for significant upside, with a mean price target of $40.31 indicating a 47.4% increase from its current price of $27.35 [1] Price Targets and Analyst Consensus - The average price target consists of 16 estimates ranging from a low of $16.00 to a high of $57.00, with a standard deviation of $13.5, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 41.5%, while the highest indicates an upside of 108.4% [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price direction, which can be a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about IMVT's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - Over the last 30 days, two earnings estimates have been revised upward, leading to a 1% increase in the Zacks Consensus Estimate [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Immunovant Inc. (NASDAQ:IMVT) is considered a promising stock under $50, with recent analyst upgrades indicating a positive shift in market sentiment regarding its potential in treating Graves' disease [1][2]. Analyst Ratings and Price Targets - Truist analyst Danielle Brill raised the price target for Immunovant to $22 from $16 while maintaining a Hold rating, indicating that the core fundamental outlook remains unchanged through 2025 [1]. - Wolfe Research upgraded Immunovant from Peer Perform to Outperform with a price target of $50, citing a shift in market sentiment and increased investor appreciation for the Graves' disease treatment space [2]. - Guggenheim analyst Yatin Suneja maintained a Buy rating but lowered the price target to $41 from $44, following a $550 million equity offering that may lead to stock dilution, though it strengthens the balance sheet and extends the cash runway [3]. Company Overview - Immunovant Inc. is a clinical-stage immunology company focused on developing monoclonal antibodies for the treatment of autoimmune diseases [4].